BBI, I wonder in the case where Amarin puts out their own Generic V,:
1) Will it still be superior (we seem to think V is superior to GV based on capsule tech) or will they be putting out the same product as the other 3 or 4 Generics?
2) Depending on the answer to 1), will a customer picking up a script be able to request or select Amarin's generic V?
BBI, yup they have a plan at least that's kind of comforting that all is not lost. It's a waiting game in more ways than one. With the branded GV name they could take back most of the gv business and make up the loss of margins with volume...
If management chooses to produce a generic, why would they continue with the patented encapsulation and refining process? I am assuming amrn's process is a more expensive process than what the generics are using. Appears that approval for a generic is easy enough to obtain. Since the company does not appear to defend their process as being superior to the generics, then why pay more to make it?
News 
Market Data 
Discover 
